Literature DB >> 31231700

Transplantation versus liver resection in patients with hepatocellular carcinoma.

Alfred Wei Chieh Kow1,2.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common solid cancers in the world. Its treatment strategies have evolved significantly over the past few decades but the best treatment outcomes remain in the surgical arena. Especially for early HCCs, the options are abundant. However, surgical resection and liver transplantation provide the best long-term survival. In addition, there are evidence the ablative therapy such as radiofrequency ablation, could provide equivalent outcome as compared to resection. However, HCC is a unique malignancy as the majority of patients develop this cancer in the background of cirrhotic livers. As such, the treatment consideration should not only look at the oncological perspective but also the functional status of the liver parenchyma, i.e., the state of cirrhosis and presence of portal hypertension. Even with the most widely adopted staging systems for HCC such as the Barcelona Clinic Liver Cancer (BCLC) staging system and many other staging systems, none of them are ideal in including the various considerations for patients with HCCs. In this article, the key issues between choosing surgical resection and liver transplantation are discussed. A comprehensive review of the current surgical options are outlined in order to explore the pros and cons of each option.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); liver; resection; transplantation

Year:  2019        PMID: 31231700      PMCID: PMC6556690          DOI: 10.21037/tgh.2019.05.06

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  11 in total

1.  Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare.

Authors:  Xiaotao Zhang; Hashem B El-Serag; Aaron P Thrift
Journal:  Cancer Causes Control       Date:  2021-01-04       Impact factor: 2.506

2.  Race and Gender Disparity in the Surgical Management of Hepatocellular Cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Program Registry.

Authors:  Michael Darden; Geoffrey Parker; Dominique Monlezun; Edward Anderson; Joseph F Buell
Journal:  World J Surg       Date:  2021-04-23       Impact factor: 3.352

3.  Familiarity Breeds Strategy: In Silico Untangling of the Molecular Complexity on Course of Autoimmune Liver Disease-to-Hepatocellular Carcinoma Transition Predicts Novel Transcriptional Signatures.

Authors:  Soumyadeep Mukherjee; Arpita Kar; Najma Khatun; Puja Datta; Avik Biswas; Subhasis Barik
Journal:  Cells       Date:  2021-07-29       Impact factor: 6.600

4.  Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation.

Authors:  Michael K Turgeon; Shimul A Shah; Aaron M Delman; Benjamin V Tran; Vatche G Agopian; Joel P Wedd; Joseph F Magliocca; Ahyoung Kim; Andrew Cameron; Ali Olyaei; Susan L Orloff; Matthew P Anderson; Chandrashekhar A Kubal; Robert M Cannon; Jayme E Locke; Mary A Simpson; Mohamed E Akoad; Chelsey P Wongjirad; Juliet Emamaullee; Amika Moro; Federico Aucejo; Cyrus A Feizpour; Parsia A Vagefi; Mindie H Nguyen; Carlos O Esquivel; Kiran Dhanireddy; Vijay Subramanian; Alejandro Chavarriaga; Marwan M Kazimi; Maia S Anderson; Christopher J Sonnenday; Steven C Kim; David P Foley; Marwan Abdouljoud; Reena J Salgia; Dimitrios Moris; Debra L Sudan; Swaytha R Ganesh; Abhinav Humar; Majella Doyle; William C Chapman; Shishir K Maithel
Journal:  Ann Surg       Date:  2021-10-01       Impact factor: 13.787

Review 5.  Role of IQ Motif-Containing GTPase-Activating Proteins in Hepatocellular Carcinoma.

Authors:  Qingqing Dai; Quratul Ain; Michael Rooney; Fei Song; Alexander Zipprich
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

6.  Stereotactic body radiation therapy versus radiofrequency ablation in patients with small hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Jiawei Hong; Linping Cao; Haiyang Xie; Yuanxing Liu; Jun Yu; Shusen Zheng
Journal:  Hepatobiliary Surg Nutr       Date:  2021-10       Impact factor: 8.265

7.  Chronic severe hepatitis and preoperative creatinine are independent risk factors for acute kidney injury after liver transplantation.

Authors:  Yingqi Chen; Shanshan Mu; Jing Wang; Anshi Wu
Journal:  Ann Transl Med       Date:  2020-12

8.  Overexpression of SSR2 promotes proliferation of liver cancer cells and predicts prognosis of patients with hepatocellular carcinoma.

Authors:  Fengsui Chen; Jielong Wang; Shi'an Zhang; Mengxue Chen; Xia Zhang; Zhixian Wu
Journal:  J Cell Mol Med       Date:  2022-04-28       Impact factor: 5.295

9.  Use of 6 m6A-relevant lncRNA genes as prognostic markers of primary liver hepatocellular carcinoma based on TCGA database.

Authors:  Xiao-Li Zhu; Qing Li; Jie Shen; Li Shan; Er-Dong Zuo; Xu Cheng
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

10.  PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma.

Authors:  Lin Zhou; Jing Wang; Shao-Cheng Lyu; Li-Chao Pan; Xian-Jie Shi; Guo-Sheng Du; Qiang He
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.